Cancers of the uterine corpus are the most common gynecologic
cancers in the United States with incidence and mortality increasing both in
the United States of America and globally. Most uterine cancers have a
favorable prognosis and are cured by surgery alone.
Identifying patients at risk of recurrence, particularly
those misclassified as low risk by current clinicopathologic standards is of
paramount importance. Physicians need better risk stratification tools to
identify when and which adjuvant therapy will decrease recurrence. Validated
biomarkers with prognostic, predictive, and/or theragnostic value will
likely play a vital role in advancing assessments of risk and guiding clinical
management decision making.
Nestin is a class VI intermediate filament protein that was
first described as a neural stem marker and regulates the TGFβ (transforming
growth factor beta) pathway. It plays a critical role in cancer cell
migration, invasion, angiogenesis, and metastasis both in vitro and in vivo.
No comments:
Post a Comment